Despite Leishvaccine and Leishmune trigger distinct immune profiles, their ability to activate phagocytes and CD8+ T-cells support their high-quality immunogenic potential against canine visceral leishmaniasis.
Phenotypic features of peripheral blood leukocytes have been investigated as a pre-requisite to characterize the protective immunity attributed to both Leishvaccine and Leishmune. Our results showed that either those vaccine were accompanied by distinct profiles on innate immune compartment. While Leishvaccine promoted early changes in phenotypic features of neutrophils and eosinophils with late involvement of monocytes, Leishmune induced early and persistent activation of neutrophils and monocytes, without changes on eosinophil activation status. Regarding the adaptive immunity, Leishvaccine sponsored a mixed profile, associated with phenotypic changes of T and B-lymphocytes. Major phenotypic changes in CD4+ T-cells with transient activation of CD8+ T-cell, besides decreased frequency of B-cell expressing CD32 were the hallmark of Leishvaccine. In contrast, Leishmune was associated with phenotypic changes in T-lymphocytes, particularly in CD8+ T-cells, and selective up-regulation of CD3+CD5+LowCD8+ cells. We hypothesized that this dissimilar alteration in immunological events would represent phenomenon directly related with the molecular nature of these vaccines besides the distinct adjuvants employed. However, it is important to emphasize that both immunobiologicals are able to activate phagocytes and CD8+ T-cells and therefore could be considered priority vaccines with a high-quality immunogenic potential against CVL.
Araújo
Márcio Sobreira Silva
MS
Laboratório de Biomarcadores de Diagnóstico e Monitoração, Instituto René Rachou, Fundação Oswaldo Cruz, Avenida Augusto de Lima 1715, 30190-002 Barro Preto, Belo Horizonte, MG, Brazil.
de Andrade
Renata Aline
RA
Vianna
Leonardo Rocha
LR
Mayrink
Wilson
W
Reis
Alexandre Barbosa
AB
Sathler-Avelar
Renato
R
Teixeira-Carvalho
Andréa
A
Andrade
Mariléia Chaves
MC
Mello
Maria Norma
MN
Martins-Filho
Olindo Assis
OA
D000818:Animals; D017252:CD3 Complex / Q000032:analysis; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018956:CD5 Antigens / Q000032:analysis; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D004283:Dog Diseases / Q000517:prevention & control*; D004285:Dogs; D004804:Eosinophils / Q000276:immunology; D005260:Female; D054332:Leishmaniasis Vaccines / Q000276:immunology*; D007898:Leishmaniasis, Visceral / Q000517:prevention & control*; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008297:Male; D009504:Neutrophils / Q000276:immunology; D010586:Phagocytes / Q000276:immunology*; D017452:Receptors, IgG / Q000032:analysis; D016176:T-Lymphocyte Subsets / Q000276:immunology
D017252:CD3 Complex; D018956:CD5 Antigens; D054332:Leishmaniasis Vaccines; D017452:Receptors, IgG